Published in AIDS Weekly, July 29th, 1996
They suggested that a carefully selected cocktail of gp120 subunits might protect against the majority of viral strains in a given population.
"We think this vaccine may be protective against some virus strains," said Genentech researcher Donald P. Francis. "The extent, breadth, and duration of such protection awaits initiation and completion of efficacy trials."
Francis and colleague Phillip W. Berman presented data from clinical trials of the Genentech subunit vaccines during separate presentations at the XI...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (1996-07-29)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.